The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Phase II trial of arsenic trioxide for chronic GvHD meets its primary endpoint

Mar 31, 2021

On March 29, 2021, it was announced that the phase II GMED16-001 trial, evaluating an intravenous formulation of arsenic trioxide in patients with chronic graft-versus-host disease (cGvHD), met its primary endpoint.

This prospective, multicenter, non-randomized study evaluated the clinical efficacy of arsenic trioxide (a new selective immunosuppressive/anti-inflammatory drug for cGvHD) administered intravenously as first-line treatment in 21 patients with moderate to severe cGvHD. The primary endpoint of the study was to show an improvement in complete or partial remission rates at 6 months.

Patients received daily intravenous infusions of arsenic trioxide over a 4-week period, in combination with prednisone with or without cyclosporine. The use of arsenic trioxide led to a drastic reduction of the prednisone dose, starting at Week 6. Discontinuation of prednisone was planned once patients achieved a complete remission.

After the 6-month follow-up, the primary efficacy endpoint was met, with a 75% overall response rate. Sustained response was also observed at 12 months post-treatment in all patients.

Based on these promising results, arsenic trioxide is expected to advance into a phase III trial to confirm its efficacy.

  1. Businesswire. Medsenic announces positive results of its phase II clinical study with Arscimed® for the treatment of chronic graft versus host disease (cGvHD). Published Mar 29, 2021. Accessed Mar 31, 2021.